Dear Sir/Madam, Pursuant to Regulation 33 and Regulation 30 read with Part-A of Schedule III of SEBI (LODR) Regulations, 2015, we hereby inform you that the Board of Directors of the ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Rekvina Laboratories' Board approved the standalone unaudited financial results for the quarter and half year ended 30 September 2025. The company reported total income of Rs. 19.62 lakhs for both Q2 and H1 FY26, compared to zero income in the corresponding periods last year. Total expenses stood at Rs. 26.65 lakhs for H1 FY26, resulting in a loss before and after tax of Rs. 7.03 lakhs for the half year (vs Rs. 7.00 lakhs loss in H1 FY25). The statutory auditor (Y. M. Shah & Co.) issued a clean limited review report with no qualifications. The balance sheet shows a sharply negative net worth of Rs. (75.28) lakhs, with borrowings more than tripling year-on-year to Rs. 81.23 lakhs and cash balance falling to just Rs. 0.18 lakhs. Operating cash flow was deeply negative at Rs. (23.85) lakhs for the half year, financed largely through fresh short-term borrowings.
Negative for shareholders — the company continues to post losses, has eroded its entire equity base, carries rising debt against negligible cash, and is dependent on borrowings to fund operations, raising serious going-concern concerns despite the first reported revenue of the year.